Literature DB >> 29418043

Advantage of recombinant von Willebrand factor for peri-operative management in paediatric acquired von Willebrand syndrome.

A C Weyand1, R Jesudas2, S W Pipe1,3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29418043     DOI： 10.1111/hae.13436

Source DB:  PubMed          Journal:  Haemophilia        ISSN： 1351-8216            Impact factor:   4.287


× No keyword cloud information.
  3 in total

Review 1.  Von Willebrand Disease: Current Status of Diagnosis and Management.

Authors:  Angela C Weyand; Veronica H Flood
Journal:  Hematol Oncol Clin North Am       Date:  2021-08-13       Impact factor: 3.722

Review 2.  Vonicog alfa for the management of von Willebrand disease: a comprehensive review and single-center experience.

Authors:  Thuy Tran; Justin Arnall; Donald C Moore; Leslie Ward; Surabhi Palkimas; Louise Man
Journal:  J Thromb Thrombolysis       Date:  2020-04       Impact factor: 2.300

3.  Distinct Mechanisms of IgM Antibody-Mediated Acquired von Willebrand Syndrome and Successful Treatment with Recombinant von Willebrand Factor in One Patient.

Authors:  Matthias Höpting; Ulrich Budde; Andreas Tiede; Matthias Grube; Joachim Hahn; Wolfgang Herr; Susanne Heimerl; Christina Hart
Journal:  Acta Haematol       Date:  2022-01-27       Impact factor: 3.068
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.